Large pharmaceutical services provider Eversana's proposed acquisition of Waltz Health, worth a staggering $6 billion, may shake up the drug pricing landscape significantly.
In a significant move for the U.S. pharmacy benefits market, Eversana has agreed to acquire Waltz Health. The combined company, valued at around $6 billion, is expected to have a substantial impact on the industry.
The acquisition of Waltz by Eversana has not disclosed a specific amount. However, the combined company, post-acquisition, will remain privately held.
The leadership team of the combined company will be headed by Mark Thierer, co-founder of Waltz. Thierer previously ran Catamaran, a pharmacy benefits manager, which was acquired by UnitedHealth Group for roughly $13 billion in 2015.
The management team led by Michael Kalb, who was previously involved in leading the Pharmacy Benefits Manager Catamaran, will take control of the combined company formed by the merger of Eversana and Waltz Health.
The acquisition could have implications for the competitive landscape in the U.S. pharmacy benefits market. The potential deal could further reshape the pharmacy benefits ecosystem in the U.S.
Mark Thierer, with his extensive experience in the pharmacy benefits market, could lead the combined company to become a significant player in the industry. The combined company, with Thierer at the helm, could be a game-changer in the U.S. pharmacy benefits market.
The terms and conditions of the acquisition are yet to be finalized and disclosed. More details about the acquisition are expected to be revealed in the coming days.
In conclusion, the acquisition of Waltz Health by Eversana is a significant development in the U.S. pharmacy benefits market. The combined company, with its substantial valuation and experienced leadership, is expected to have a substantial impact on the industry. The acquisition could reshape the competitive landscape and further consolidate the pharmacy benefits market.
